• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

52.25 -0.10 (-0.19%)
Delayed Quote Updated: 3:59 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 640,963
Open 52.36
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 52.35
Today's Range 51.83 - 52.46
52wk Range 40.07 - 60.85
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Genentech and Breastcancer.org Say It’s “About Damn Time” We Talk About What Happens When Initial Breast Cancer Treatment Ends
October 01, 2026
From Genentech
Via Business Wire
News headline image
Genentech Presents New Data at EURETINA, Highlighting Vabysmo’s Real-World Effectiveness and Safety Across Major Retinal Conditions
October 01, 2026
From Genentech
Via Business Wire

Performance

52-Week Range 14.1% below 52-week high
52.25
40.0752W Low 60.8552W High
1 Week 2.6% below 1-week high
51.811W Low 53.621W High

Roche Holding AG Basel American Depositary Shares (RHHBY) traded between $40.07 and $60.85 over the past 52 weeks and last traded at $52.25, 14.1% below its 52-week high. Over the past week it ranged between $51.81 and $53.62.

Past 12 Months
-2.1%
-2.9%
+1.3%
+4.5%
+1.6%
+16.9%
1W -$1.12
1M -$1.58
3M +$0.66
6M +$2.27
YTD +$0.80
1Y +$7.55

RHHBY was +16.9% over the past year, +4.5% over six months, +1.6% year to date, -2.1% in the last week.

12 Months vs Market
RHHBY
+16.9%
DIA
+9.9%
SPY
+15.0%
QQQ
+23.7%
IWM
+15.4%

Over the past 12 months RHHBY returned +16.9% versus DIA (Dow) +9.9%, SPY (S&P 500) +15.0%, QQQ (Nasdaq 100) +23.7% and IWM (Russell 2000) +15.4%.

Volume & Liquidity 0.32× 3-mo avg
Today 640,963 3-mo avg 2.0M
1W
1.7M
1M
1.6M
3M
2.0M
6M
2.1M
YTD
2.3M
1Y
2.3M

RHHBY most recently traded 640,963 shares against a 3-month average daily volume of 2.0M.

More News

Read More
News headline image
Genentech’s Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine
October 01, 2026
From Genentech
Via Business Wire
News headline image
Could This Company Challenge Eli Lilly and Novo Nordisk in the Weight Loss Market? ↗
September 30, 2026
Via The Motley Fool
News headline image
Genentech’s Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosis
September 30, 2026
From Genentech
Via Business Wire
News headline image
Genentech Breaks Ground on $750 Million Manufacturing Expansion in Hillsboro, Oregon
September 28, 2026
From Genentech
Via Business Wire
News headline image
Positive Interim Data Shows Genentech’s Sefaxersen Significantly Reduces Proteinuria in People With IgA Nephropathy (IgAN)
September 23, 2026
From Genentech
Via Business Wire
News headline image
Is Regeneron Stock a Bargain Below $800? ↗
September 22, 2026
Via The Motley Fool
Topics Intellectual Property
News headline image
Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity
September 22, 2026
From Genentech
Via Business Wire
News headline image
BioNTech Threw in the Towel on Its Colorectal Cancer Vaccine Trial. Should Investors Be Worried? ↗
September 18, 2026
Via The Motley Fool
News headline image
Genentech and Roche Announce Grand Opening of Boston R&D Innovation Center
September 17, 2026
From Genentech
Via Business Wire
News headline image
Genentech’s Lunsumio-Based Regimen Significantly Improves Progression-Free Survival in Follicular Lymphoma in Phase III CELESTIMO Study
September 17, 2026
From Genentech
Via Business Wire
News headline image
U.S. FDA Grants Priority Review for Genentech’s Enspryng for MOGAD, an Autoimmune Disease With No Approved Treatments
September 10, 2026
From Genentech
Via Business Wire
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
September 08, 2026
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
September 08, 2026
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
September 08, 2026
Via Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
September 08, 2026
Via Investor Brand Network
News headline image
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
September 08, 2026
From BioMedWire
Via GlobeNewswire
News headline image
Revolution Medicines Got Its Breakthrough—What Moves It Next? ↗
September 04, 2026
Via MarketBeat
News headline image
Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone ↗
September 03, 2026
Via The Motley Fool
News headline image
2 Stocks That Could Capitalize on the GLP-1 Boom ↗
August 25, 2026
Via The Motley Fool
News headline image
Genentech Announces Manufacturing Expansion in Hillsboro, Oregon
August 20, 2026
From Genentech
Via Business Wire
News headline image
Genentech Marks Topping out Milestone for New Holly Springs, North Carolina Manufacturing Facility
August 18, 2026
From Genentech
Via Business Wire
News headline image
2 GLP-1 Stocks That Could Double Your Money by 2031 ↗
August 16, 2026
Via The Motley Fool
News headline image
Vanguard Is Bullish on Developed Markets Outside the U.S. -- But How Can You Buy Them? These 2 ETFs Can Help. ↗
August 14, 2026
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy

Frequently Asked Questions

Is Roche Holding AG Basel American Depositary Shares publicly traded?
Yes, Roche Holding AG Basel American Depositary Shares is publicly traded.
What exchange does Roche Holding AG Basel American Depositary Shares trade on?
Roche Holding AG Basel American Depositary Shares trades on the OTC Traded
What is the ticker symbol for Roche Holding AG Basel American Depositary Shares?
The ticker symbol for Roche Holding AG Basel American Depositary Shares is RHHBY on the OTC Traded
What is the current price of Roche Holding AG Basel American Depositary Shares?
The current price of Roche Holding AG Basel American Depositary Shares is 52.25
When was Roche Holding AG Basel American Depositary Shares last traded?
The last trade of Roche Holding AG Basel American Depositary Shares was at 10/02/26 03:59 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap